ConductScience.org, home

Comparison · NCT05327296-1a0da123

Isoflurane vs Propofol: Other Secondary: The Effect of Isoflurane vs Propofol on Mortality at 3 Months After Randomization

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Isoflurane vs Propofol: Other Secondary: The Effect of Isoflurane vs Propofol on Mortality at 3 Months After Randomization. Trial comparisons, record NCT05327296-1a0da123. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05327296-1a0da123

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.3010.2370.373wilson
Risk in group 20.310.2230.414wilson
Risk difference, group 1 minus group 2-0.00977-0.1310.104newcombe hybrid score
Risk ratio, group 1 over group 20.9690.6581.43log
Odds ratio, group 1 over group 20.9550.5461.67log
Number needed to treat, for one fewer participant with the outcome on Isoflurane than on Propofol102from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1IsofluraneInhaled isoflurane administered via Sedaconda ACD-S~Isoflurane: Inhaled isoflurane administered by Sedaconda ACD-S52173OG000
Group 2PropofolPropofol administered as intravenous infusion~Propofol: Intravenous infusion of propofol2787OG001

Outcome

Type
SECONDARY
Title
Other Secondary: The Effect of Isoflurane vs Propofol on Mortality at 3 Months After Randomization
Description
Participants reported represent participants that died between randomization and 3 months in the Safety population
Time frame
At 3 months after randomization
Population

Source ClinicalTrials.gov

Trial

Title
Efficacy and Safety of Inhaled Isoflurane Delivered Via the Sedaconda ACD-S Compared to Intravenous Propofol for Sedation of Mechanically Ventilated Intensive Care Unit Adult Patients (INSPiRE-ICU2)
NCT number
NCT05327296
Phases
PHASE3
Conditions
Sedation
Interventions
Isoflurane, Propofol
Lead sponsor
Sedana Medical
Results first posted
2026-03-03

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT05327296-1a0da123